Research Article

The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET

Table 2

Bone marrow toxicity of [90Y]Y/[177Lu]Lu-DOTATATE.

PRRT (n = 26)n (%)
HgB12 (7.7)
HgB1, transient, WBC11 (3.8)
HgB1, WBC12 (7.7)
HgB2, transient1 (3.8)
WBC12 (7.7)
WBC2, transient1 (3.8)
WBC1, PLT1, transient2 (7.7)

R-PRRT (n = 26)
HgB19 (34.6)
HgB1, WBC12 (7.7)
HgB1, WBC1, PLT12 (7.7)
HgB22 (7.7)
WBC1, transient1 (3.8)
WBC1, PLT11 (3.8)
WBC22 (7.7)

RR-PRRT (n = 5)
HgB13
HgB21
MDS1